SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)
| Valuation | |
|---|---|
| Market Cap ($M) | 59.67 |
| Enterprise Value ($M) | 52.75 |
| Book Value ($M) | 6.45 |
| Book Value / Share | 0.18 |
| Price / Book | 9.25 |
| NCAV ($M) | 6.05 |
| NCAV / Share | 0.16 |
| Price / NCAV | 9.86 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -1.36 |
| Return on Assets (ROA) | -1.07 |
| Return on Equity (ROE) | -1.47 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 6.61 |
| Current Ratio | 6.61 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 7.34 |
| Assets | 7.74 |
| Liabilities | 1.29 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Knoll Capital Management, LLC | 15.00 | 51.52 | |
| 13G/A | Centillion Fund Inc. | 6.70 | 0.00 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 2,819 | 34,478 | 8.18 | |
| 27,813 | 41,946 | 66.31 | |
| 2,026 | 48,104 | 4.21 | |
| 9,116 | 24,326 | 37.47 | |
| 14,210 | 49,870 | 28.49 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| ENLV – Enlivex Therapeutics Ltd. | ENSC – Ensysce Biosciences, Inc. |
| ENTO – Entero Therapeutics, Inc. | ENVB – Enveric Biosciences, Inc. |
| EPIX – ESSA Pharma Inc. |
Financial data and stock pages provided by
Fintel.io